|1.||Mauger, David T: 1 article (04/2003)|
|2.||Padmanabhan, Vasantha: 1 article (04/2003)|
|3.||Van Cleeff, Judith: 1 article (04/2003)|
|4.||Brown, Morton B: 1 article (04/2003)|
|5.||Neill, Jimmy D: 1 article (04/2003)|
|6.||Karsch, Fred J: 1 article (04/2003)|
|7.||Evans, Neil P: 1 article (04/2003)|
|8.||Dahl, Geoffrey E: 1 article (04/2003)|
|1.||Leiomyoma (Uterine Fibroids)
10/01/1993 - "Continuous treatment with Nal-Glu induces immediate and sustained pituitary-gonadal down-regulation that results in regression in leiomyoma size. "
10/01/1993 - "The efficacy of acute and sustained pituitary gonadotropin down-regulation by the Nal-Glu GnRH antagonist (Nal-Glu) was evaluated in the treatment of uterine leiomyomas. "
|2.||Body Weight (Weight, Body)
05/01/1990 - "In subchronic studies, groups of 12 male and 12 female rats received 0, 50, 250, or 1250 micrograms/kg body weight (BW) Nal-Glu for 90 days and were killed on Day 91. "
04/01/2003 - "Hypophyseal portal and jugular blood was collected from five ovariectomized and six luteal phase ewes at 5-min intervals for 6 h before and 6 h after a single iv injection of Nal-Glu (10 micro g/kg body weight). "
07/01/1995 - "We administered Nal-Glu at doses of 0, 100, and 200 micrograms/kg body weight per day in combination with T enanthate, 50 mg IM weekly, to separate groups of men (9 or 10 men per group) for 4 weeks. "
05/01/1990 - "Nal-Glu treatment led to a significantly decreased body weight gain in the males and a significantly increased body weight gain in the females. "
09/01/1995 - "In that experiment, hypophyseal portal blood was collected from five short-term ovariectomized ewes at 5-min intervals for 6 h before and 6 h after intravenous injection of Nal-Glu (10 micrograms/kg body weight). "
08/01/1992 - "Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate."
01/01/1994 - "The Nal-Glu gonadotropin-releasing hormone (GnRH) antagonist, when given in daily subcutaneous (SC) doses of 5 mg or higher, maximally suppresses serum luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels to near undetectable levels and induces azoospermia in normal men; lower doses (1.5 and 3.0 mg) are less effective. "
02/01/1994 - "Alpha-subunit levels were not modified by Nal-Glu administration in the 2 patients with alpha-subunit-secreting adenomas.(ABSTRACT TRUNCATED AT 250 WORDS)"
02/01/1994 - "A single administration of 5 mg Nal-Glu to the 7 patients with FSH-secreting adenomas produced a slight but significant fall in above-normal FSH levels from 24.4 +/- 15.4 IU/l to a nadir of 20.3 +/- 11.9 IU/l (-17%, p < 0.05) 20 h following the injection. "
05/01/1993 - "The failure of Nal-Glu to reduce adenoma size despite its success in reducing FSH secretion suggests that FSH secretion from gonadotroph adenomas is dependent on endogenous GnRH, but growth of gonadotroph adenomas is not."
05/01/1993 - "Because administration for 1 week of the GnRH antagonist Nal-Glu GnRH had been shown to decrease FSH secretion from supranormal to normal in men with gonadotroph adenomas, we investigated the effect of prolonged administration of Nal-Glu on the size of gonadotroph adenomas. "
|1.||N- Ac- 2- Nal(1)- 4- Cl- Phe(2)- 3- Pal(3)- Arg(5)- Glu(6)- AlaNH2(10)- LHRH
|3.||Gonadotropin-Releasing Hormone (GnRH)
|4.||Luteinizing Hormone (Lutropin)
|5.||Follicle Stimulating Hormone (Follitropin)
|6.||testosterone enanthate (Delatestryl)